Christopher J. Twomey, director of Tandem Diabetes Care, Inc. (NASDAQ: TNDM), sold 3,198 shares of Tandem Diabetes Care stock on Wednesday, April 21. The stock sold at an average price of $ 95.02 for a total transaction of $ 303,873.96. The transaction was announced in a filing with the SEC, which is available through this link.
Tandem Diabetes Care stock traded at $ 1.34 during mid-day trading on Friday to hit $ 94.96. The company’s stock had a trading volume of 598,437 shares versus an average volume of 765,404 shares. The company has a leverage ratio of 0.61, a current rate of 5.61, and a fast rate of 4.94. The stock has a market cap of $ 5.94 billion, a price to earnings ratio of -117.23, and a beta of 0.31. The company has a 50-day moving average price of $ 87.81 and a 200-day moving average price of $ 96.84. Tandem Diabetes Care, Inc. has a 12-month low of $ 69.69 and a 12-month high of $ 123.74.
Tandem Diabetes Care (NASDAQ: TNDM) last released its quarterly results on Tuesday, February 23rd. The medical device company reported earnings of $ 0.22 per share for the quarter, beating the consensus estimate of $ 0.12 by $ 0.10. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%. The company posted revenue of $ 168.07 million for the quarter, compared to the consensus estimate of $ 141.13 million. On average, stock analysts expect Tandem Diabetes Care, Inc. to achieve earnings per share of -0.35 for the current fiscal year.
Hedge funds have recently increased or decreased their stake in the business. Candriam Luxembourg SCA increased its position in shares of Tandem Diabetes Care by 63.7% in the fourth quarter. Candriam Luxembourg SCA now owns 52,370 shares in the medical device company valued at $ 5,011,000 after acquiring an additional 20,370 shares during the period. Eaton Vance Management increased its position in Tandem Diabetes Care stocks by 22.8% in the fourth quarter. Eaton Vance Management now owns 342,526 shares of the medical device company, valued at $ 32,773,000, after acquiring an additional 63,496 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Tandem Diabetes Care by 31.8% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 128,420 shares in the medical device company valued at $ 12,287,000 after acquiring an additional 31,000 shares during the reporting period. Banque Cantonale Vaudoise increased its position in shares of Tandem Diabetes Care by 5.9% in the fourth quarter. Banque Cantonale Vaudoise now owns 2,929 shares in the medical device company valued at $ 281,000 after purchasing an additional 164 shares during the period. Finally, the North Carolina state treasurer increased his position in Tandem Diabetes Care stocks by 2.3% in the fourth quarter. The North Carolina state treasurer now owns 22,250 shares in the medical device company, valued at $ 2,129,000, after purchasing an additional 510 shares during the reporting period. Hedge funds and other institutional investors own 88.60% of the company’s shares.
(Display)
They named the 2020 crash 45 days earlier. Nobody expects what they are predicting now …
TNDM has been the subject of several analyst reports. Oppenheimer reassigned a buy rating to shares of Tandem Diabetes Care in a report on Wednesday March 31st. SVB Leerink lowered its price target for shares of Tandem Diabetes Care from USD 115.00 to USD 95.00 and set a “market perform” rating for the company in a report on Thursday, April 1st. Lake Street Capital raised its target price on shares of Tandem Diabetes Care from $ 137.00 to $ 150.00 and rated the company a “Buy” in a report on Thursday, February 25th. Eventually, Zacks Investment Research downgraded Tandem Diabetes Care’s stock from a “buy” rating to a “hold” rating and set a price target of $ 101.00 for the company. in a report on Monday March 1st. Five investment analysts have rated the stock with a hold rating and nine with a buy rating. Tandem Diabetes Care has a consensus rating of “Buy” and an average price target of $ 114.86.
Tandem Diabetes Care company profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and markets a variety of products for people with insulin-dependent diabetes in the United States. The company’s flagship is the t: slim X2 insulin delivery system, a pump platform that includes the t: slim X2 pump, the disposable 300-unit insulin cartridge and an infusion set.
Further Reading: What Is the NASDAQ Stock Market?
This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]
Sponsored Article: Why Invest in High Yield Dividend Stocks?
7 low-priced dividend stocks under $ 10
Recent trading activity in cheap stocks like GameStop (NYSE: GME) is reminding investors of the high risk associated with these stocks. Often times, when a stock is trading for less than $ 10 (also known as a penny stock) it is trading that low for a reason. The company may not be profitable or, in the case of GameStop, have a business model that is no longer in line with consumer trends.
But that’s not always the case. It is possible to find cheap stocks, even penny stocks, that offer great value. This is especially true if the stock offers investors a dividend. Dividend-earning stocks are a source of diversification for a consumer’s portfolio, especially when the dividend is reinvested. It’s literally like paying yourself to own the stock.
And the stocks in this presentation also seem poised for additional stock price growth that can add to your overall return.
Check out the “7 Inexpensive Dividend Stocks Under $ 10”.
